Mumbai: In another instance of ‘repurposing’ an existing therapy, Mumbai-based Bharat Serums and Vaccines (BSV) has received regulatory approval to initiate clinical trials of critical care drug, Ulinastatin, for Covid-19 patients.
Ulinastatin is used in India for severe sepsis and other critical clinical conditions like acute pancreatitis. Managing director and chief executive officer Sanjiv Navangul told TOI that the company received approval from the drug regulator to conduct a clinical study on Ulinastatin, for mild-to-moderate acute respiratory distress syndrome (ARDS) patients with Covid-19.
The company joins other domestic firms including Glenmark, Sun Pharma, Biocon and NovaLead Pharma that are conducting trials of potential drugs for Covid-19. While there is no approved and proven treatment against SARS-CoV-2 virus yet, only experimental drugs are being used as supportive therapy.
Clinical trials on 120 patients are expected to start at hospitals over the next three weeks, and results will be available by December. Though there is no scientific study on Ulinastatin yet, certain countries like China are believed to have used it for Covid-19 therapy.